Literature DB >> 7638032

Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics.

G H McCracken1.   

Abstract

Penicillin resistance among strains of Streptococcus pneumoniae has emerged as an important worldwide problem. Beta-lactam-resistant pneumococci also can be resistant to erythromycin, trimethoprim/sulfamethoxazole and tetracycline and are uniformly susceptible to vancomycin and imipenem. Crowded conditions (e.g. daycare centers, hospitals, military barracks and prisons) and prior beta-lactam antibiotic therapy are the principal predisposing factors to colonization and disease. To date the two conditions caused by penicillin- and cephalosporin-resistant pneumococci that have been especially difficult to treat are acute otitis media and meningitis. Concentrations of beta-lactams in cerebrospinal fluid and middle ear fluid are usually inadequate to achieve prompt eradication of some intermediately resistant and most highly resistant pneumococcal strains. Use of unconventional therapeutic agents such as ceftriaxone or clindamycin for acute otitis media and vancomycin or rifampin for meningitis may be necessary. Control of this global problem will require innovative methods to reduce the selective pressure that results from widespread antibiotic use and to develop effective pneumococcal vaccines that are immunogenic in young infants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638032     DOI: 10.1097/00006454-199505001-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  13 in total

1.  In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae.

Authors:  E O Mason; L B Lamberth; S L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

2.  Risk factors for resistance to "first-line" antimicrobials among urinary tract isolates of Escherichia coli in children.

Authors:  U D Allen; N MacDonald; L Fuite; F Chan; D Stephens
Journal:  CMAJ       Date:  1999-05-18       Impact factor: 8.262

3.  Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats.

Authors:  R A Saladino; A M Stack; G R Fleisher; C M Thompson; D E Briles; L Kobzik; G R Siber
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

4.  Prevention of Pneumococcal Meningitis.

Authors:  Tina Q. Tan
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

5.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics.

Authors:  Anita L Kozyrskyj; Matthew E Dahl; Dan G Chateau; Garey B Mazowita; Terry P Klassen; Barbara J Law
Journal:  CMAJ       Date:  2004-07-20       Impact factor: 8.262

Review 7.  Practical considerations when treating children with antimicrobials in the outpatient setting.

Authors:  L N Werk; H Bauchner
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

8.  Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation.

Authors:  E Bingen; C Levy; E Varon; F de La Rocque; M Boucherat; P d'Athis; Y Aujard; R Cohen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-11-30       Impact factor: 3.267

Review 9.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

10.  Discrepancies between results by E-test and standard microbroth dilution testing of Streptococcus pneumoniae for susceptibility to vancomycin.

Authors:  F B Hashemi; G E Schutze; E O Mason
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.